FDA PCAC Recommends Six Peptide Groups for the 503A Bulks List

On July 23 and 24, 2026, the U.S. Food and Drug Administration's Pharmacy Compounding Advisory Committee (PCAC) recommended adding six of seven reviewed peptide-related bulk drug substance groups to the Section 503A Bulks List. The favorable recommendations covered BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax. The committee did not recommend Emideltide, also known as delta sleep-inducing peptide (DSIP). [11]

The votes are consequential but not final FDA action. PCAC advises FDA; its recommendations are nonbinding. The meeting also was not a drug-approval proceeding, so none of the seven substances became FDA approved. FDA must now decide whether and how to act on the committee's recommendations through the applicable regulatory process. [1]

Current Status

Item	Status as of July 24, 2026
PCAC meeting	Concluded July 24, 2026
FDA staff position	FDA staff recommended against adding all reviewed forms
PCAC recommendation	Recommend six substance groups; do not recommend Emideltide/DSIP
FDA final determination	Pending
FDA drug approval	None; this was not a drug-approval meeting
Last checked	July 24, 2026

PCAC's recommendations differed from FDA staff's preliminary position. The committee favored inclusion for six peptide-related groups despite the characterization, evidence, and safety concerns described in FDA's briefing packages. Emideltide/DSIP was the only group that did not receive a favorable recommendation. [2][11]

Importantly, a favorable PCAC vote does not itself place a substance on the 503A Bulks List. FDA retains decision-making authority, and qualifying compounding would still have to satisfy the other requirements of Section 503A. [1][3]

In This Article

• Current status
• What PCAC is
• What Section 503A means
• The seven substances, votes, and reviewed uses
• What FDA staff concluded
• What happens after the meeting
• Questions and answers

What Is PCAC?

The Pharmacy Compounding Advisory Committee advises FDA on scientific, technical, and medical issues involving drug compounding under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Its members review FDA analyses, nomination materials, public comments, and presentations before voting or otherwise giving recommendations.

Advisory committees do not replace FDA's decision-making authority. A PCAC vote can influence the agency's next step, but FDA may consider additional evidence and legal or policy issues after the public meeting.

What Is Section 503A?

Section 503A describes conditions under which qualifying patient-specific compounded drugs may receive exemptions from several requirements that ordinarily apply to commercially manufactured drugs. It is not a pathway for approving a drug.

FDA explains that a pharmacist or physician operating under Section 503A may compound from a bulk drug substance only under specified conditions. In broad terms, the substance must comply with an applicable USP or NF monograph, be a component of an FDA-approved drug when no applicable monograph exists, or appear on the FDA's 503A Bulks List. Other conditions also apply, including requirements involving the source of the bulk substance and a valid certificate of analysis. [3]

This distinction matters:

• FDA approval evaluates a finished drug for a defined indication, formulation, manufacturing process, labeling, and benefit-risk profile.
• 503A Bulks List inclusion addresses whether a bulk drug substance may be used in qualifying compounding when other statutory conditions are met.
• PCAC review gives FDA expert advice during development of the bulks list.

None of those terms is interchangeable.

Which Substances Were Reviewed?

FDA divided the meeting across two days and identified the uses it evaluated for each substance group. The free-base and acetate forms were listed as distinct bulk drug substances in the meeting materials. The vote totals below report the committee's recommendation on each related group. [1][11]

Date	Substance group	Use or uses FDA evaluated	PCAC vote	Recommendation	Research profile
July 23	BPC-157	Ulcerative colitis	8–6, 1 abstention	Recommend inclusion	BPC-157 research
July 23	KPV	Wound healing and inflammatory conditions	8–6, 1 abstention	Recommend inclusion	KPV research
July 23	TB-500	Wound healing	8–6, 1 abstention	Recommend inclusion	TB-500 research
July 23	MOTS-c	Obesity and osteoporosis	7–5, 2 abstentions	Recommend inclusion	MOTS-c research
July 24	Emideltide (DSIP)	Opioid withdrawal, chronic insomnia, and narcolepsy	6–7, 1 abstention	Do not recommend inclusion	Emideltide research
July 24	Semax	Cerebral ischemia, migraine, and trigeminal neuralgia	8–5	Recommend inclusion	Semax research
July 24	Epitalon	Insomnia	7–5, 1 abstention	Recommend inclusion	Epitalon research

The evaluated uses do not represent every claim made about these peptides online. They reflect the uses FDA found sufficiently defined for this review. For example, FDA's BPC-157 document says it did not evaluate several other nominated uses because the nomination lacked enough information and FDA did not identify relevant clinical studies. [4]

What Do the FDA Briefing Documents Say?

FDA applies four criteria when evaluating a substance for the 503A Bulks List: physical and chemical characterization, safety issues, available evidence of effectiveness or lack of effectiveness, and historical use in compounded drug products. The criteria are balanced rather than treated as a single pass-or-fail test. [2]

Across the seven reviews, several themes recur:

Characterization and product quality

FDA identified inconsistent naming, uncertainty about whether nominations referred to free-base or acetate forms, and missing or inadequate information about identity, purity, peptide-related impurities, aggregates, microbial quality, or dosage-form performance. These concerns are especially relevant for peptides because formulation, manufacturing, storage, and aggregation can alter quality and potential immunogenicity.

Human evidence

The evidence varies by substance, but it is generally limited. FDA reported no human administration data for KPV, TB-500, or MOTS-c in the reviewed literature. [5][6][10] Emideltide has older small human studies, but FDA described the effectiveness evidence as insufficient and the study methods as inconsistent or preliminary. [7] Semax has some human literature, much of it from a limited research setting, while FDA still concluded that the overall balance weighed against listing. [9]

Safety uncertainty

An absence of reported adverse events does not establish safety. FDA repeatedly noted limited surveillance, lack of clinical exposure data, unknown long-term risks, and potential concerns related to impurities, aggregation, and immune responses. The individual briefing documents should be read as regulatory evidence reviews, not as clinical treatment guidance.

FDA staff's position and the committee's recommendation

FDA staff concluded that the available information weighed against adding every reviewed free-base and acetate form to the 503A Bulks List. [2] PCAC reached a different recommendation for six groups after hearing the presentations, public testimony, and committee discussion. The disagreement does not erase the evidence limitations in FDA's reviews, and neither position is the agency's final determination. [11]

Why This Is Not an Approval Meeting

Drug approval would require a sponsor to submit a marketing application supported by evidence for a specific product, indication, dose, route, manufacturing process, and labeling. PCAC is instead considering whether bulk substances should appear on a statutory list used in pharmacy compounding.

PCAC's favorable recommendations—and any later FDA decision to add a substance to the list—would not establish a favorable clinical benefit-risk profile for a disease, authorize general commercial marketing, or convert products sold online as “research peptides” into approved medicines.

Likewise, a recommendation against inclusion would address eligibility for the Section 503A framework. It would not erase the underlying preclinical literature, and it would not substitute for a substance-specific enforcement or approval analysis in every other legal context.

What Happens After the Meeting?

PCAC has completed its advisory role for these seven groups. The next steps belong to FDA:

1. FDA will review the votes, committee discussion, public testimony, and the existing evidence record.
2. Official minutes, transcripts, and other meeting records may be posted after the meeting.
3. FDA may proceed through the regulatory process required to add substances to or exclude them from the 503A Bulks List.
4. The agency may accept, reject, narrow, or otherwise differ from the committee's recommendations.

There is no guaranteed date for final FDA action. Until FDA acts, the committee votes should be described as recommendations—not as a legalization, approval, or immediate change in compounding status. [1]

Meeting Outcome

PCAC recommended six of the seven peptide-related substance groups for inclusion on the Section 503A Bulks List: BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax. Emideltide/DSIP did not receive a favorable recommendation. [11]

The votes exposed a clear disagreement between a majority of committee members and FDA staff. Supporters emphasized clinician judgment and the potential value of access through regulated pharmacy compounding. Opponents emphasized weak human evidence, uncertain product characterization, safety gaps, and the availability of approved therapies for some reviewed uses. The outcome is advisory; FDA has not yet made its final determination.

What Changed

July 24, 2026: PCAC completed voting. Six groups received favorable recommendations; Emideltide/DSIP did not. FDA final action remains pending.

July 21, 2026: FDA's individual briefing packages and meeting-level questions were reviewed. FDA staff proposed not adding any of the reviewed free-base or acetate entries.

Next Regulatory Steps

The key milestone is now FDA's response to the committee recommendations. This page will be updated when FDA publishes official minutes or transcripts, announces an interim policy, or takes formal action on the 503A Bulks List.

Until then, the accurate description is:

• PCAC recommended inclusion for six groups.
• PCAC did not recommend inclusion for Emideltide/DSIP.
• FDA final determinations are pending.
• None of the substances is FDA approved as a result of these votes.

What Researchers Should Understand

The briefing packages are valuable because they separate laboratory findings, limited clinical observations, product-quality questions, and marketing claims. They also illustrate why a mechanistic result in an in vitro model or animal study cannot establish clinical effectiveness.

Researchers reading the documents should ask:

• Was the exact chemical form identified?
• Was the tested material the same substance described by compounders?
• Were studies conducted in humans or only in cells and animals?
• Did the study evaluate the same route and use under review?
• Are adverse-event data meaningful given underreporting and limited exposure?
• Were the results independently replicated?

Our guides to reading peptide research, evaluating peptide claims, and understanding clinical trials provide additional context.

Frequently Asked Questions

Did FDA approve or legalize six peptides?

No. PCAC recommended that six peptide-related substance groups be added to the 503A Bulks List. The recommendation is nonbinding, FDA has not yet taken final action, and list inclusion would not constitute FDA approval of a finished drug.

Did FDA ban Emideltide/DSIP?

No new ban resulted from the meeting. PCAC did not recommend Emideltide/DSIP for inclusion, but FDA still controls the final regulatory determination.

Are these peptides FDA approved?

No. The meeting did not consider new drug applications. A compounding-list decision is different from FDA approval of a finished drug for a specific indication.

Does a favorable 503A recommendation prove a peptide works?

No. The committee recommendation concerns possible eligibility for qualifying compounding under Section 503A. It does not establish safety or effectiveness for a finished product, dose, route, or condition.

Why are free-base and acetate forms listed separately?

FDA treats them as distinct bulk drug substances because their chemical and physical characteristics may differ. The meeting materials therefore identified both forms within each peptide-related group.

When will the final answer be known?

FDA has not provided a guaranteed date for final action. The July votes are an advisory milestone, followed by agency review and any required regulatory action.